Xylitol Chewing-gums: Concentration in Saliva and Antibacterial Effect
Xylitol Chewing-gums: Concentration in Saliva and Antibacterial Effect (In-vivo and In-vitro Study)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Sardinia
-
Sassari, Sardinia, Italy, I-07100
- Department of Surgery, Microsurgery and Medicine Sciences University of Sassari
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- good general health,
- the absence of diseases that can alter the saliva secretion rate
- a stimulated saliva flow at least of 1 ml/min.
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: 100% Xylitol
The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
|
Subjects were instructed to consume the gums as they normally would be consumed.
|
|
EXPERIMENTAL: 22% Xylitol
The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
|
Subjects were instructed to consume the gums as they normally would be consumed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of Salivary concentration of Xylitol
Time Frame: 9 days
|
Xylitol concentration using spectrophotometer analysis was determined in saliva before, at 0.30, 1.00, 2.00, 5.00, 10.00 minutes using the chewing-gum, and after the gum discarded at 15.00, 20.00 and 25.00 minutes.
|
9 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Guglielmo Campus, Università degli Studi di Sassari
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SS-15884-GC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontal Diseases
-
NCT07446127RecruitingPeriodontal Disease | Periodontal Attachment Loss | Periodontal Pockets
-
NCT07254117RecruitingPeriodontitis | Periodontal Diseases | Periodontal Bone Loss | Periodontal Disease | Periodontal Regeneration | Periodontal Healing | Periodontal Granulation Tissue | Vertical Periodontal Bone Defects
-
NCT07468929Not yet recruitingPeriodontal Disease | Periodontal Surgery
-
NCT05858411RecruitingPeriodontal Diseases | Intrabony Periodontal Defect | Periodontal Attachment Loss | Pocket, Periodontal
-
NCT07146776RecruitingPeriodontitis | Periodontal Diseases | Periodontal Bone Loss | Intrabony Periodontal Defect | Periodontal Defect
-
NCT07520968Active, not recruitingPeriodontal Disease | Periodontal Disease, AVDC Stage 3 | Periodontal Disease Stage 2
-
NCT07581613Not yet recruitingPeriodontal Disease | Intrabony Periodontal Defects
-
NCT07358104Active, not recruitingPeriodontal Diseases | Periodontal Attachment Loss
-
NCT06404190CompletedPeriodontitis | Periodontal Attachment Loss | Periodontal Inflammation | Pocket, Periodontal
-
NCT05233501CompletedPeriodontal Diseases | Periodontal Attachment Loss | Periodontal Inflammation | Periodontal Disease, AVDC Stage 3 | Periodontal Disease, AVDC Stage 4
Clinical Trials on 100% Xylitol Gum
-
NCT02333227CompletedPreterm Birth | Periodontal Disease | Caries, Dental
-
NCT07424846Not yet recruitingPeriodontitis | Gingivitis | Preterm Birth | Developmental Delay | Low Birthweight Neonate
-
NCT06329596Active, not recruitingDysbiosis | Inflammation Gum | Microbioata | Placenta-mediated Pregnancy Complications | Neurodevelopmental Changes (Childhood, Ageing)
-
NCT06579339CompletedControl Group | Xylitol Gum Chewing | Non-xylitol Gum Chewing
-
NCT02468388Completed
-
NCT05361122RecruitingNeurodevelopmental Disorders | Prematurity
-
NCT06370091Completed
-
NCT05946473Not yet recruitingDental Caries | Dental Plaque | Periodontal Disease